Introduction {#section5-1178633720904081}
============

Influenza is the second most deadly pandemic in human history -- the so-called Spanish Flu.^[@bibr1-1178633720904081]^ Influenza is a disease caused by a single strain RNA genome virus belonging to the *Orthomyxoviridae* family. Four types have been identified (A, B, C, and D), with only types A and B causing significant infections in humans. This virus is classified according to hemagglutinin and neuraminidase protein characteristics.^[@bibr2-1178633720904081]^ In 2009, an antigenic shift of influenza A H1N1 led to a global influenza pandemic.^[@bibr3-1178633720904081],[@bibr4-1178633720904081]^ Influenza virus strain H1N1pdm09 is responsible for 20% to 40% of the mortality rate and poses a worldwide challenge for intensive care units (ICUs).^[@bibr5-1178633720904081][@bibr6-1178633720904081]-[@bibr7-1178633720904081]^ However, vaccination coverage remains low despite recommendations.^[@bibr8-1178633720904081],[@bibr9-1178633720904081]^ Furthermore, new virus sub-types cause outbreaks that pose different public health challenges.^[@bibr10-1178633720904081]^

Acute respiratory failure progressing into acute respiratory distress syndrome (ARDS) is the most common presentation in ICUs.^[@bibr11-1178633720904081],[@bibr12-1178633720904081]^ In some cases, this is associated with myocarditis, which can lead to heart failure.^[@bibr13-1178633720904081]^ Treatment is based on neuraminidase inhibitor administration as soon as influenza is suspected, protective lung ventilation, and general organ support.^[@bibr14-1178633720904081],[@bibr15-1178633720904081]^ In the most severe cases, veno-venous extracorporeal membrane oxygenation (VV-ECMO) can be implanted.^[@bibr16-1178633720904081],[@bibr17-1178633720904081]^

Herein, we did a retrospective study including adult patients admitted to 3 referral ICUs of a tertiary care teaching hospital for severe influenza. The primary goal was to describe the characteristics of these patients, their clinical presentation, and the 3-month mortality rate. The second objective was to investigate the 3-month mortality risk factors.

Materials and Methods {#section6-1178633720904081}
=====================

Study setting {#section7-1178633720904081}
-------------

This was a retrospective observational study including all adult patients admitted with severe influenza to one of the 3 ICUs at Toulouse University Hospital, France, between October 2013 and June 2016. This study was approved by the 'Commission nationale d'informatique et des libertés' (French Data Protection Authority) (No. 2173146v0). According to French legislation, the need for consent was waived.

Definitions and management {#section8-1178633720904081}
--------------------------

Influenza cases were defined as a clinical influenza-like illness with an influenza-positive laboratory test (nasal swab, tracheal suction, or bronchoalveolar lavage, with reverse transcription polymerase chain reaction testing \[RT-PCR\]).

Acute respiratory distress syndrome was defined according to the Berlin consensus, and patients were treated as per the experts' recommendations.^[@bibr18-1178633720904081]^

The implementation of VV-ECMO was discussed on the basis of regional protocol and Extracorporeal Life Support Organization (ELSO) guidelines, in the case of severe ARDS with refractory hypoxaemia or uncontrolled hypercarbia despite conventional management including prone positioning.^[@bibr16-1178633720904081],[@bibr17-1178633720904081]^

Myocarditis was defined as a change in the ST segment associated with elevated serum troponin levels and normal coronary angiography (or no compatible lesion). In the case of refractory cardiogenic shock, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) implementation was discussed.

All patients with VV-ECMO or VA-ECMO located in our region were transferred to and managed in our ICU.

In our unit, neuraminidase inhibitor (oseltamivir) was given as soon as influenza was suspected. Treatment was continued until the RT-PCR tested negative, with a minimum of 5 days. The test was carried out twice a week once diagnosis was confirmed.

Data collection {#section9-1178633720904081}
---------------

Demographic data, the length of time from onset of clinical signs to ICU admission or initiation of anti-neuraminidase treatment, invasive ventilation and vasopressor infusion, concomitant bacterial infection, strain lineage, and the administration of ARDS adjunct therapy were recorded. Thirty-day and 3-month mortality were collected from medical records if available or by calling patients or their relative or medical referent when patients were not available.

Statistical analysis {#section10-1178633720904081}
--------------------

Following initial descriptive statistics comprising variable distribution analysis (Shapiro-Wilk test), the study population was divided into 2 groups: 3-month survivors and non-survivors. The characteristics of both groups were compared using the Mann-Whitney test for quantitative variables and the Fisher test and χ^2^ test for qualitative variables. Results are expressed as median values with interquartile range or as percentages, where appropriate. Significant quantitative explanatory variables were assessed with receiver operating characteristic curves and associated area under the curve (AUC) to determine the optimal cut-off value associated with 3-month mortality prior to multivariate analysis. Survival probability based on the significant explanatory variable was assessed using the Kaplan-Meier method.

Covariate selection for the multivariate analysis was based on a value of *P* \< .2 with univariate analysis. The prognostic value of the covariates of interest was assessed using the Cox proportional hazards model. The results are presented as hazard ratios (HR) with a 95% confidence interval (CI).

Patients with the best chances of survival were highlighted by separating the population according to Classification and Regression Tree (CART) analysis.^[@bibr19-1178633720904081]^ The purpose of this approach was to describe the method for distributing the population between homogeneous groups based on 3-month survival and the covariates previously selected for the multidimensional analysis.

Statistical analyses were conducted using SPSS for Windows version 23.0 (IBM Corporation, Armonk, NY, USA). A value of *P* \< .05 was considered statistically significant.

Results {#section11-1178633720904081}
=======

Baseline characteristics of the study population {#section12-1178633720904081}
------------------------------------------------

Sixty-nine patients satisfied the inclusion criteria between October 2013 and June 2016. They were mostly men (*n* = 42, 60.9%), middle-aged (60 \[48-68\] years), and non-institutionalised (*n* = 64, 92.8%) ([Table 1](#table1-1178633720904081){ref-type="table"}). Fourteen patients (20.3%) were hospitalised in the month prior to the studied hospital admission.

###### 

Summary of demographic, clinical, and biological data of 3-month survivors and non-survivors.

![](10.1177_1178633720904081-table1)

                                                                                                                    Survivors               Non-survivors           *P* value
  ----------------------------------------------------------------------------------------------------------------- ----------------------- ----------------------- -----------
  Age, y, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                                       56 (43 to 66)           67 (58 to 76)           **.01**
  BMI, kg/m^2^, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                                 24 (22 to 31)           25.5 (22 to 29.5)       .93
  SAPS II, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                                      36 (31 to 53)           71 (51 to 79)           **\<.01**
  Male, No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^                                              22 (44.9)               5 (25)                  .17
  Medical history                                                                                                                                                   
   Hospitalisation in the month prior to admission No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^   10 (20.4)               4 (20)                  .99
   COPD, No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^                                             7 (14.3)                6 (30)                  .17
   Heart failure, No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^                                    7 (14.3)                7 (35)                  .09
   Arterial hypertension, No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^                            13 (26.5)               12 (60)                 **.01**
  Vaccination, No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^                                       4 (8.6)                 1 (5.8)                 **1**
  Clinical presentation at ICU admission^[c](#table-fn4-1178633720904081){ref-type="table-fn"}^                                                                     .33
   Acute respiratory failure, No. (%)                                                                               12 (17.4)               2 (2.9)                 
   ARDS, No. (%)                                                                                                    34 (49.3)               16 (23.2)               
   Myocarditis, No. (%)                                                                                             3 (4.3)                 2 (2.9)                 
  Days between onset and ICU admission, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^         4 (3 to 7)              6.5 (2 to 8)            **.17**
  Virus^[c](#table-fn4-1178633720904081){ref-type="table-fn"}^                                                                                                      .68
   Non-typed influenza A, No. (%)                                                                                   21 (42.9)               9 (45)                  
   H1N1, No. (%)                                                                                                    15 (30.6)               3 (15)                  
   H3N2, No. (%)                                                                                                    1 (2)                   2 (10)                  
   Influenza B, No. (%)                                                                                             12 (24.5)               6 (30)                  
  Presentation at admission                                                                                                                                         
   Body temperature, °C, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                        38.5 (38.1 to 39)       38.8 (37.9 to 39.2)     .82
   Leukocyte, cell/mm^3^, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                       8890 (5170 to 13 720)   9670 (5512 to 14 212)   .72
   pH, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                                          7.42 (7.31 to 7.48)     7.4 (7.24 to 7.45)      .37
   Pa[o]{.smallcaps}~2~, mm Hg, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                 58 (50 to 71)           57 (44 to 66)           .54
   Pa[o]{.smallcaps}~2~/Fi[o]{.smallcaps}~2~, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^   120 (100 to 130)        90 (50 to 100)          **.03**
   Pa[co]{.smallcaps}~2~, mm Hg, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                37 (31 to 49)           36 (29 to 43)           .49
   Alkaline reserve, mmol/L, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                    22 (20 to 29)           20 (17 to 24)           **.04**
   Base excess, mmol/L, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                         −1.3 (−4 to 3.1)        −4.2 (−8.9 to −1.4)     **.01**
   Lactates, mmol/L, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                            1.5 (1 to 2.2)          2.4 (1.8 to 4)          **\<.01**
   Creatinine, µmol/L, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                          76 (60 to 91)           145 (96 to 265)         **\<.01**
   Troponin T, ng/L, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                            12 (7 to 49)            65 (19 to 279)          **.02**
   AST, IU/L, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                                   50 (34 to 93)           130 (82 to 275)         **\<.01**
   ALT, IU/L, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                                   34 (22 to 73)           77 (56 to 116)          **\<.01**
   Bilirubin, µmol/L, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                           8 (5 to 13)             13 (9 to 17)            **.01**
  No. of days with norepinephrine, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^              3 (1 to 5)              5 (3 to 9)              **.02**
  Days under mechanical ventilation, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^            10 (4 to 25)            9 (8 to 17)             .87
  Days with neuromuscular blocking agent, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^       5.5 (2 to 10)           6 (2.25 to 10)          .82
  Nitric oxide, No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^                                      10 (20.4)               5 (25)                  .67
  Prone positioning sequence, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                   2 (2 to 2)              1 (1 to 2)              .06
  Patient receiving NI, No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^                              43 (87.7)               16 (80)                 .46
  Days between onset and NI debut, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^              5 (3 to 7)              7 (2 to 8)              .85
  NI duration, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                                  10 (7 to 14)            8 (5 to 12)             .31
  ECMO^[c](#table-fn4-1178633720904081){ref-type="table-fn"}^                                                       14 (28.6)               9 (45)                  .26
   Veno-venous, No. (%)                                                                                             7 (14.3)                7 (35)                  
   Veno-arterial, No. (%)                                                                                           2 (4.1)                 2 (10)                  
   Prone positioning and ECMO, No. (%)^[b](#table-fn3-1178633720904081){ref-type="table-fn"}^                       10 (20.4)               7 (35)                  .23
   No. of days with ECMO, median (IQR)^[a](#table-fn2-1178633720904081){ref-type="table-fn"}^                       9 (6 to 13)             7 (3 to 9)              .16

Abbreviations: ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation; Fi[o]{.smallcaps}~2~, O~2~ inspired fraction; ICU, intensive care unit; IQR, interquartile range; NI, neuraminidase inhibitor; Pa[co]{.smallcaps}~2~, CO~2~ partial pressure; a[o]{.smallcaps}~2~, O~2~ partial pressure; SAPS II, Simplified Acute Physiology Score II.

Mann-Whitney test.

Fisher test.

χ^2^ test

Bold values are statistically significant (*p* \< 0.05).

A history of arterial hypertension (*n* = 25, 36.5%), heart failure (*n* = 14, 20.3%), and chronic obstructive pulmonary disease (*n* = 13, 18.8%) was documented in most cases.

Presentation and management of influenza {#section13-1178633720904081}
----------------------------------------

Five patients (7.2%) were vaccinated in the year of admission, although 54 patients (78.3%) should have been vaccinated according to French guidelines.

In terms of clinical presentation, 50 patients (72.5%) were admitted for ARDS, 5 (7.2%) for myocarditis, and 14 (20.3%) for acute respiratory failure without ARDS criteria.

The median length of time between clinical onset and ICU admission was 5 (2-7) days. Twenty-eight patients (40.6%) were initially admitted to another facility. The median Simplified Acute Physiology Score II (SAPS II) on admission was 44 (33-66).

Non-typed influenza A was found in 30 cases (43.5%), influenza A H1N1 in 18 patients (26.1%), H3N2 in 3 patients (4.3%), and influenza B in 18 patients (27.5%).

Nearly 70% of patients required invasive ventilation for a median duration of 10 (4-25) days. Prone position was required for 26 patients (37.7%) and nitric oxide was administered to 15 patients (21.7%). Extracorporeal membrane oxygenation was implanted in 23 patients (33.3%), namely 19 VV-ECMO and 4 VA-ECMO.

Neuraminidase inhibitor was given to 58 patients (84.1%), for a median duration of 9 (6-14) days. Five patients did not receive treatment because of a late diagnosis, and no specific reason was retrieved for the remaining 6 patients. The 30-day and 3-month mortality rates were 24.6% (*n* = 17) and 29% (*n* = 20), respectively.

Predictors for 3-month mortality {#section14-1178633720904081}
--------------------------------

Univariate analysis revealed a significant correlation between 3-month mortality and higher patient's age (odds ratio \[OR\]: 1.05, 95% confidence interval \[CI\], 1.02-1.1, *P* = .008), higher SAPS II (OR: 1.07, 95% CI: 1.04-1.11, *P* \< .001), a medical history of arterial hypertension and/or cardiac medication (OR: 4.15, 95% CI: 1.41-12.92, *P* = .011), lower Pa[o]{.smallcaps}~2~/Fi[o]{.smallcaps}~2~ ratio (OR: 0.98, 95% CI: 0.95-0.99, *P* = .026), higher serum lactate level (OR: 1.49, 95% CI: 1.11-2.15, *P* = .017), higher serum creatinine level (OR: 1.009, 95% CI: 1.003-1.012, *P* = .009), lower glomerular filtration rate (estimated by CKD EPI \[Chronic Kidney Disease Epidemiology Collaboration\] formula) (OR: 0.96, CI 95%: 0.94-0.98, *P* \< .001), higher troponin level (OR: 1.009, 95% CI: 1.003-1.012, *P* = .009), higher aspartate aminotransferase (AST) (OR: 1.01, 95% CI: 1.005-1.016, *P* = .012) and alanine aminotransferase (ALT) (OR: 1.008, 95% CI: 1.002-1.01, *P* = .026), bilirubin levels on admission (OR: 1.003, 95% CI = 1.001-1.005, *P* = .033), and the duration of norepinephrine infusion (in days) (OR: 1.84; 95% CI: 1.26-2.09, *P* = .039). Virus type and lineage was not linked to worst outcome.

A sub-group analysis of patients treated with ECMO did not highlight any increase in mortality compared with patients without ECMO (39% vs 24%, respectively; *P* = .19), even with a higher SAPS II value (predicted in-hospital mortality of 70% for patients with ECMO versus 19.6% for those without) ([Figure 1](#fig1-1178633720904081){ref-type="fig"} and [Table 2](#table2-1178633720904081){ref-type="table"}). Patients treated with ECMO had higher BMI, higher creatinine serum level, lower Pa[o]{.smallcaps}~2~/Fi[o]{.smallcaps}~2~ ratio, and higher AST, ALT, and bilirubin level at ICU admission than patients without ECMO, without significant difference in hemodynamic parameters, lactate level, or pH.

![Kaplan-Meier survival curve at 3 months. Blue line indicates patient without ECMO; red line indicates patients with ECMO. Time in days. A value of *P* \< .05 was considered statistically significant. ECMO indicates extracorporeal membrane oxygenation.](10.1177_1178633720904081-fig1){#fig1-1178633720904081}

###### 

Demographic data of ECMO and non-ECMO patients.

![](10.1177_1178633720904081-table2)

                                              Non-ECMO (*n* = 46)   ECMO (*n* = 23)   *P* value               
  ------------------------------------------- --------------------- ----------------- ----------- ----------- ------------
  Age                                         62                    50-75             53          47-64       .09
  BMI                                         24                    22-29.5           29          24-32       **.039**
  SAPS II                                     37                    31.5-51           61          45.5-72.5   **.002**
  Heart rate                                  101                   85-114            97          90-113      .86
  SAP                                         115                   90-129            120         100-125     .96
  DAP                                         70                    60-80             70          60-80       .59
  Creatinine                                  78.5                  58.5-97           93          76-165      **.049**
  GFR                                         82.5                  49.5-105          61          38-90.5     .12
  Troponin                                    28                    9-92              18.8        7.5-86.5    .73
  Lactates                                    1.5                   1-2.5             2           1.5-3.5     .09
  Pa[o]{.smallcaps}~2~                        60.9                  58-73.5           53          38.5-63.5   .06
  Pa[o]{.smallcaps}~2~/Fi[o]{.smallcaps}~2~   125                   100-134           68          50-71       **\<.001**
  Pa[co]{.smallcaps}~2~                       37                    31-49             33.4        30-42       .09
  pH                                          7.40                  7.29-7.47         7.44        7.39-7.5    .12
  AST                                         50.5                  36-96             93          66-233      **.01**
  ALT                                         34                    22.5-69.5         77          53.5-115    **.002**
  Bilirubin                                   7.85                  5-13              13          11-18       **.001**
  ICU length of stay                          10                    6-20              20          11-32       **.02**
  Number of days of MV                        6                     2-10              24          11-32       **\<.001**

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DAP, diastolic arterial pressure; ECMO, extracorporeal membrane oxygenation; GFR, glomerular filtration rate; ICU, intensive care unit; IQR, interquartile range; MV, mechanical ventilation; SAP, systolic arterial pressure; SAPS II, Simplified Acute Physiology Score II.

Bold values were statistically significant (*p* \< 0.05).

Multivariate Cox proportional hazard regression analysis using backward elimination was performed to identify the risk factors predicting 3-month mortality. This model confirmed that an AST level superior to 68 IU/L and a creatinine level superior to 96 μmol/L on admission are associated with 3-month mortality (HR: 7.68 \[1.68-35.1\] and 4.73 \[1.61-13.92\], respectively, with *P* \< .01 for each). The AUC for this model was 0.89 (95% CI: 0.79-0.95), with a sensitivity of 70%, a specificity of 92%, a positive predictive value of 78%, and a negative predictive value of 88% ([Figure 2](#fig2-1178633720904081){ref-type="fig"} and [Table 3](#table3-1178633720904081){ref-type="table"}).

![Survival curve according to Cox model variable, 1 (red line): creatinine \>96 μmol/L, AST \>68 IU/L, and P/F ⩽110; 0 (blue line): creatinine \<96 μmol/L, AST \<68 IU/L, and P/F \>110. Time in days. A value of *P* \< .05 was considered statistically significant. AST indicates aspartate aminotransferase; P/F, O~2~ partial pressure/O~2~ inspired fraction ratio.](10.1177_1178633720904081-fig2){#fig2-1178633720904081}

###### 

Multivariate analysis with Cox model for 3-month mortality-associated factor.

![](10.1177_1178633720904081-table3)

                                                           Hazard ratio   95% CI       *P* value
  -------------------------------------------------------- -------------- ------------ -----------
  Significant covariables                                                              
   AST \>68 IU/L                                           7.68           1.68-35.1    \<.01
   Creatinine \>96 µmol/L                                  4.73           1.61-13.92   \<.01
  Non-significant variable included in segmentation tree                               
   P/F ⩽110                                                1.36           0.47-3.92    .57

Abbreviations: AST, alanine aminotransferase; CI, confidence interval; P/F, O~2~ partial pressure/O~2~ inspired fraction ratio.

A value of *P* \< .05 was considered statistically significant.

With the segmentation tree and using the CART method, we increased the positive predictive value to 85.5% by including a new variable: Pa[o]{.smallcaps}~2~/Fi[o]{.smallcaps}~2~ ratio \<110 ([Figure 3](#fig3-1178633720904081){ref-type="fig"}). We defined 7 sub-groups by dividing the study population step by step according to the variables included in the model. Those sub-groups differed considerably for outcome: the sub-group with no risk factor (*n* = 21), as defined by our model, had a 100% survival rate compared with 21.3% for the sub-group presenting all the risk factors (*n* = 15). The other sub-groups had intermediate outcomes, depending on how many risk factors they presented.

![Prediction model of 3-month mortality by segmentation tree (Classification and Regression Tree analysis) according to creatinine level, AST level, and P/F ratio. A value of *P* **\>** .05 is significant and means predictive value improvement of the step. AST indicates alanine aminostransferase; NSv, 3-month non-survivors; P/F, O~2~ partial pressure/O~2~ inspired fraction ratio; Sv, 3-month survivors.](10.1177_1178633720904081-fig3){#fig3-1178633720904081}

Discussion {#section15-1178633720904081}
==========

This article reports on a retrospective cohort of 69 patients admitted to ICU for severe influenza, with 3 main clinical presentations: ARDS (72.5%), acute respiratory failure without ARDS criteria (21.7%), and myocarditis (7.2%). Influenza ARDS and respiratory failure are clearly described, especially during the 2009 pandemic, whereas viral myocarditis is less well known.^[@bibr4-1178633720904081],[@bibr11-1178633720904081],[@bibr14-1178633720904081],[@bibr15-1178633720904081],[@bibr20-1178633720904081]^

In their review of extrapulmonary influenza complications, Sellers et al^[@bibr13-1178633720904081]^ highlight 44 reported cases of influenza-related myocarditis, with VA-ECMO implemented in 16 of them. In our study, 4 patients benefited from VA-ECMO, of whom 2 died. Pathophysiology is not well documented, but direct viral invasion seems to be the *primum movens.*^[@bibr13-1178633720904081]^

The mortality rate in our study was 29% (32% for patients admitted for ARDS, 40% for those admitted for myocarditis, and 11.8% for those admitted for non-ARDS acute respiratory failure). Studies on influenza in ICUs report various mortality rates, but the rate remains high, between 8% and 50%, depending on the population studied, resources, the chosen time for end point, and the type of virus.^[@bibr3-1178633720904081],[@bibr4-1178633720904081],[@bibr6-1178633720904081],[@bibr21-1178633720904081][@bibr22-1178633720904081]-[@bibr23-1178633720904081]^ Most of these studies focused on influenza A H1N1, and more specifically on the 2009 pandemic. We report on cases of all influenza virus clinical presentations encountered over a 4-year period in a large regional tertiary hospital ICU.

In our study, we found no difference in mortality rate between patients with and without ECMO, despite the fact that patients with ECMO were more severely ill. The conventional ventilation or ECMO for severe adult respiratory failure (CESAR) trial showed improved survival rates with VV-ECMO in ARDS, but did not focus on influenza.^[@bibr24-1178633720904081]^ The main limit of this study is that all patients in the interventional group were transferred to the same unit for ECMO, making it difficult to extrapolate the results. Furthermore, in some cases, ECMO was not implemented because conventional management was sufficient when applied according to the guidelines. Conversely, the recent ECMO to rescue lung injury in severe ARDS (EOLIA) trial did not find an improved survival rate and was stopped early for futility.^[@bibr25-1178633720904081]^ However, cross-over between the control group and the interventional group (ie, conventional ventilation and ECMO) was permitted in EOLIA study, making it difficult to interpret those results. In their study, Noah et al^[@bibr26-1178633720904081]^ highlighted improvement in mortality rates in influenza ARDS with ECMO in a retrospective cohort with a propensity score matching. Pham et al^[@bibr27-1178633720904081]^ found no difference in mortality rate using a similar method, but some patients treated with ECMO were not included in their propensity score analysis because there was no match for comparison, and those patients had better outcomes, with more severe respiratory criteria, than those included.

Several predictive mortality scores exist for ARDS patients treated with VV-ECMO,^[@bibr28-1178633720904081]^ and one was specifically designed for influenza.^[@bibr29-1178633720904081]^ This score includes hospital length of stay before VV-ECMO, haematocrit, and mean arterial pressure as well as creatinine and bilirubin. In our 3-month mortality-predicting model, we included serum creatinine and AST on admission, which were significantly associated with death when superior to 96 µmol/L and 68 IU/L, respectively. Extracorporeal membrane oxygenation may be effective in this indication because ECMO implementation was not significantly associated with mortality and was not included in our model. However, the patients who would most benefit from this should be better defined.

Acute kidney injury (AKI) is a well-known associated mortality factor in ICU.^[@bibr30-1178633720904081]^ Several studies have described the same association with influenza, especially ARDS-related influenza A H1N1 during the 2009 pandemic.^[@bibr31-1178633720904081][@bibr32-1178633720904081]-[@bibr33-1178633720904081]^ Acute tubular necrosis seems to be the main pathological finding in an autopsy series of patients with AKI who died in the 2009 pandemic.^[@bibr34-1178633720904081]^ Pathophysiology is poorly understood, but AKI is probably multifactorial involving renal hypoperfusion, hypoxia, rhabdomyolysis, vasoconstriction, and SIRS (systemic inflammatory response syndrome). Liver injury is described to a less extent, but seems to be associated with worse outcomes.^[@bibr35-1178633720904081],[@bibr36-1178633720904081]^ In their study, Gao et al^[@bibr35-1178633720904081]^ found that an AST rate superior to 40 IU/L was associated with a worse outcome for patients with ARDS and influenza A H7N9. In their retrospective study including 97 patients with seasonal and 2009 pandemic influenza, Papic et al^[@bibr36-1178633720904081]^ found a correlation between serum liver enzyme and hypoxia. Interestingly, they found that serum liver enzyme elevation was significantly higher in the 2009 pandemic influenza than in seasonal flu. Once again, the mechanisms involved have yet to be defined, but appear to include hypoxia and SIRS. Cor pulmonale is already known to induce biological abnormalities, including AST and creatinine elevation, and is frequently associated with ARDS and poor outcome.^[@bibr37-1178633720904081]^ Here we assume that this provides one explanation for our findings, but our study was not designed for this purpose, and further studies are needed.

The strength of our study is its description of severe H1N1 and non-H1N1 influenza-related ICU patients, with several clinical presentations. Myocarditis was not rare, emphasising the need to take into consideration influenza in epidemic season for patient with this clinical presentation. We have developed a simple and efficient predictive mortality model, including clinical and biological data availed in daily practice. The association of a high AST level and 3-month mortality raises questions about pathophysiologic mechanisms in influenza infection that require specific studies on this subject, especially the hypothesis of a right heart--specific injury.

However, our study presents several limitations. Data are missing because of its retrospective design. Only 69 patients with heterogeneous presentations and characteristics were enrolled. It is a single-centre study, and as we are a tertiary centre, our patients may not represent patients admitted to other facilities. This may reduce the accuracy of our model. Furthermore, the low rate of events (ie, death at 3 months) due to the small number of patients meant that we could not include more than 2 variables in the model.

Conclusions {#section16-1178633720904081}
===========

Influenza is still a life-threatening disease. Respiratory failure is the main cause of ICU admission, although myocarditis is not rare. While previous scientific reports and media attention focus on H1N1 influenza, seasonal and new emergent variant-related influenza should be borne in mind when it comes to causes of severe infection. Three simple, practical, and available in daily practice variables were found to be significant predictors of 3-month mortality. These could prove useful in providing a more accurate evaluation of severity to tailor additional therapies. Extracorporeal membrane oxygenation may be beneficial in the most severe cases.
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